CCWM
CHRS icon

Cassaday & Co Wealth Management’s Coherus Oncology CHRS Stock Holding History

Cassaday & Co Wealth Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280 Sell
200
-180
-47% -$294 ﹤0.01% 1183
2026
Q1 		$643 Buy
+380
New +$675 ﹤0.01% 1172

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Cassaday & Co Wealth Management's CHRS Position: Q2 2026 in Review

Cassaday & Co Wealth Management reduced its Coherus Oncology (CHRS) stake by 47% in Q2 2026, selling an estimated $294 and leaving 200 shares worth $280. The position accounts for ﹤0.01% of the portfolio, ranked #1183.

Cassaday & Co Wealth Management first reported a position in CHRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $643 in Q1 2026. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Cassaday & Co Wealth Management held 200 shares of Coherus Oncology worth $280 as of Q2 2026.
  • Cassaday & Co Wealth Management sold 180 Coherus Oncology shares in Q2 2026, an estimated $294.
  • Coherus Oncology made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1183 holding.
  • Cassaday & Co Wealth Management first reported a position in Coherus Oncology in Q1 2026 and has held it in 2 quarters since.
  • Cassaday & Co Wealth Management's Coherus Oncology position peaked at $643 in Q1 2026.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.